Guanfacine

BNF:

Not listed

Status:

Amber

Decision Date:

September 2018

Comments

See Shared Care guideline for drugs used in the management of ADHD in children and adults

3rd line option for the treatment of attention- deficit hyperactivity disorder in children aged 5 years and over and young adults

 

Amber Drug Classifications

• 1: Requiring specialist assessment to enable patient selection and initiation of treatment
• 3: Requiring short or medium term specialist monitoring of toxicity

search again